CNTX

Context Therapeutics Inc.

1.95 USD
-0.01 (-0.51%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Context Therapeutics Inc. stock is down -2.5% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 June’s closed higher than May.

About Context Therapeutics Inc.

Context Therapeutics Inc. develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of progesterone receptor. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody.